Home / Brand archive
4 reported ongoing
4 records in this archive. Latest source date Jun 24, 2026.
FDA enforcement status can lag behind the recall lifecycle. An empty search or a reported termination is not a personal product-safety determination.
Archive changed Oct 1, 2026. USDA FSIS records are unavailable; check FSIS directly. Source coverage and dates.
Cross Contamination with Other Products: Customer complaints for appearance of discolored tablets and red dots observed on Cetirizine Hydrochloride Tablets USP 5 mg. Determined to be Ranitidine.
Class IReported ongoing
Distribution: Nationwide in the USA
Failed Impurities/Degradation Specifications:Out of specification result occurred in Organic Impurities Test
Class IIReported ongoing
Distribution: Nationwide in the USA
Tablet/Capsules Imprinted with Wrong ID
Class IIIReported ongoing
Distribution: U.S. Nationwide
Tablet/Capsules Imprinted with Wrong ID
Class IIIReported ongoing
Distribution: U.S. Nationwide
These examples come from this result page and are not a ranking of every recall reason.
This archive contains 4 records, including 4 with agency-reported ongoing status. The status field can be incomplete or stale. Open the current official notice and match your exact product.
Compare the product, firm and lot, date, model or serial identifiers with the notice. Use the label-check guide if you need help locating an identifier.
A name is a search match. The agency notice sets the affected products and identifiers. Do not assume that every item with the same name or brand belongs to the recall.
This search has source and keyword limits. Missing records or a missing lot code do not establish that a product is unaffected. Check source coverage and the agency's current notices.
Use monthly archives or the local search. The initial import covers records dated from October 2021 where available; each source's actual first and latest dates appear on the coverage page.